Five-year clinical outcomes using the bioresorbable vascular scaffold: Insights from the FRANCE ABSORB registry - 10/11/22
on behalf of the
FRANCE ABSORB investigators
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Graphical abstract |
Central illustration: cumulative major adverse cardiac events (MACE) and bioresorbable vascular scaffold (BVS) thrombosis rates after 1, 2, 3, 4 and 5 years.
Highlights |
• | Absorb BVS implantation was associated with low rates of 1-year major adverse cardiac events (MACE). |
• | MACE increased significantly at 3-year follow-up after Absorb BVS implantation. |
• | The rates of scaffold thrombosis and MACE after 3 years decreased significantly. |
Summary |
Background |
Randomized trials comparing the first-generation absorb bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA, USA) with a drug-eluting stent showed a moderate but significant increase in the rate of 3-year major adverse cardiac events and scaffold thrombosis, followed by a decrease in adverse events after 3 years.
Aim |
The objective of this study was to assess the 5-year outcomes of patients treated with at least one absorb BVS and included in the FRANCE ABSORB registry.
Methods |
All patients treated in France with an absorb BVS were prospectively included in a large nationwide multicentre registry. The primary efficacy outcome was the occurrence of 5-year major adverse cardiac events. Secondary efficacy outcomes were the rates of 5-year target vessel revascularization and definite/probable scaffold thrombosis.
Results |
Between September 2014 and April 2016, 2,070 patients were included in 86 centres (mean age 55±11 years; 80% men; 49% with acute coronary syndrome). The rates of 1-, 3- and 5-year major adverse cardiac events were 3.9%, 9.4% and 12.1%, respectively (including cardiac death in 2.5% and target vessel revascularization in 10.4%). By multivariable analysis, diabetes, oral anticoagulation, the use of multiple Absorb BVSs and the use of a 2.5mm diameter absorb BVS were associated with 5-year major adverse cardiac events. The rates of 1-, 3- and 5-year definite/probable scaffold thrombosis were 1.5%, 3.1% and 3.6%, respectively. By multivariable analysis, older age, diabetes, anticoagulation at discharge and the use of a 2.5mm diameter absorb BVS were associated with 5-year scaffold thrombosis.
Conclusions |
Absorb BVS implantation was associated with low rates of 1-year major adverse cardiac events, which increased significantly at 3-year follow-up. There was a clear decrease in the rates of scaffold thrombosis and major adverse cardiac events after 3 years.
El texto completo de este artículo está disponible en PDF.Keywords : Bioresorbable vascular scaffold, Percutaneous coronary intervention, Angioplasty, Registry
Abbreviations : ACS, BMS, BVS, DAPT, DES, MACE, PSP
Esquema
| ☆ | Tweet: bioresorbable vascular scaffold is not dead: 5-year results of the FRANCE ABSORB registry. |
Vol 115 - N° 10
P. 505-513 - octobre 2022 Regresar al número
Artículo precedente
- Immediate versus staged complete myocardial revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease: A post hoc analysis of the randomized FLOWER-MI trial
- Victoria Tea, Jean-François Morelle, Romain Gallet, Guillaume Cayla, Gilles Lemesle, Thibault Lhermusier, Jean-Guillaume Dillinger, Grégory Ducrocq, Denis Angouvant, Yves Cottin, Chekrallah Chamandi, Alicia le Bras, Philippe Gabriel Steg, Gilles Montalescot, Anaïs Charles Nelson, Tabassome Simon, Gilles Chatellier, Nicolas Danchin, Etienne Puymirat, for the FLOWER-MI study investigators
- Prevalence of psychoactive drug use in patients hospitalized for acute cardiac events: Rationale and design of the ADDICT-ICCU trial, from the Emergency and Acute Cardiovascular Care Working Group and the National College of Cardiologists in Training of the French Society of Cardiology
- Jean-Guillaume Dillinger, Théo Pezel, Charles Fauvel, Clément Delmas, Guillaume Schurtz, Antonin Trimaille, Edouard Gerbaud, Vincent Roule, Jean-Claude Dib, Albert Boccara, Damien Millischer, Christophe Thuaire, Julien Fabre, Thomas Levasseur, Tanissia Boukertouta, Arthur Darmon, Ruben Azencot, Benoit Merat, Marie Haugel-Moreau, Alain Grentzinger, Clément Charbonnel, Cyril Zakine, Marc Bedossa, Benoît Lattuca, François Roubille, Victor Aboyans, Etienne Puymirat, Ariel Cohen, Eric Vicaut, Patrick Henry, for the ADDICT-ICCU investigators
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.